# US 2008/0187528 A1 · Anti-tsg101 antibodies and their uses for treatment of viral infections > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2008/0187528 A1 - Document ID: US20080187528A1 - Status: Published application - Kind: A1 - Application number: 11/940,714 - Filed: 2007-11-15 - Published: 2008-08-07 - Earliest claimed: 2006-11-15 - Assignees: Functional Genetics, Inc. - Inventors: Limin Li; Michael Kinch; Michael Goldblatt - Web page: https://patentgrep.com/patent/US20080187528A1 ## CPC - C07K 16/28: against receptors, cell surface antigens or cell surface determinants - A61P 31/12: Antivirals - A61P 31/14: for RNA viruses - A61P 31/18: for HIV - C07K 16/18: against material from animals or humans - A61K 2039/505: {comprising antibodies} - C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues - C07K 2317/56: variable (Fv) region, i.e. VH and/or VL - C07K 2317/565: Complementarity determining region [CDR] - C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC] - C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The present invention provides antibodies that bind to the C-terminal region of TSG101. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV and Ebola virus infection. ## Claims ### Claim 1 A method for inhibiting virus infection in a mammalian subject, comprising providing to said subject an effective amount of an anti-TSG101 antibody, wherein said antibody binds TSG101 present on cells of said subject which may become infected with said virus. ### Claim 2 (depends on 1) The method of claim 1, wherein the anti-TSG111 antibody is a monoclonal antibody. ### Claim 3 (depends on 2) The method of claim 2, wherein the monoclonal antibody is selected from the group consisting of antibodies C, D1, E, SG1 and CB8. ### Claim 4 (depends on 2) The method of claim 2, wherein the monoclonal antibody binds to an epitope in the C-terminal region of TSG101. ### Claim 5 (depends on 1) The method of claim 1, wherein the anti-TSG101 antibody is a humanized antibody. ### Claim 6 (depends on 5) The method of claim 5, wherein the humanized antibody comprises at least one amino acid sequence selected from the group consisting of SEQ ID NOS:30-41. ### Claim 7 (depends on 6) The method of claim 6, wherein the humanized antibody comprises amino acid sequences recited in SEQ ID NOS:30-35. ### Claim 8 (depends on 6) The method of claim 6, wherein the humanized antibody comprises amino acid sequences recited in SEQ ID NOS:36-41. ### Claim 9 (depends on 1) The method of claim 1, wherein said virus is a human immunodeficiency virus, marburg virus, ebola virus, influenza virus, respiratory syncytial virus, encephalitis virus, rous sarcoma virus, lassa fever virus, hepatitis virus, Epstein-barr virus, vaccine virus, herpes virus or junin virus. ### Claim 10 (depends on 1) The method of claim 1, wherein said mammal is a non-human and said virus is pseudorabies virus, pseudorabies virus II, swine rotavirus, swine parvovirus, bovine viral diarrhea virus, Newcastle disease virus h, swine flu virus, swine flu virus, foot and mouth disease virus, hog colera virus, swine influenza virus, African swine fever virus, infectious bovine rhinotracheitis virus, infectious laryngotracheitis virus, La Crosse virus, neonatal calf diarrhea virus, Venezuelan equine encephalomyelitis virus, punta toro virus, murine leukemia virus, mouse mammary tumor virus, equine influenza virus or equine herpesvirus, bovine respiratory syncytial virus, bovine parainfluenza virus, PRRS virus, porcine or bovine circoviruses, porcine or bovine coronaviruses, porcine or bovine RSV, porcine, bovine or avian influenza, EIAV, or bluetongue. ### Claim 11 (depends on 1) The method of claim 1, wherein said anti-TSG101 antibody is provided to said mammal by administering said antibody to dais mammal. ### Claim 12 (depends on 1) The method of claim 1, where said anti-TSG101 antibody is provided to said mammal by inoculating said mammal with a TSG101 immunogen that induces an immune response in said human including the preparation of antibodies which bind to an epitope of TSG101. ### Claim 13 An anti-TSG101 monoclonal antibody, said antibody binds to a TSG101 C-terminal region consisting of an amino acid sequence recited in SEQ ID NO:3. ### Claim 14 (depends on 13) The anti-TSG101 monoclonal antibody of claim 13, wherein in said monoclonal antibody comprises a polypeptide comprising an amino acid sequence recited in SEQ ID NO: 19, 22, 25 or 28. ### Claim 15 A monoclonal antibody that binds to TSG101 selected from the group consisting of antibodies C, D1, E, 3G1 and CB8. ### Claim 16 (depends on 14) The monoclonal antibody of claim 14, wherein said antibody is a humanized antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:30-41. ### Claim 17 A pharmaceutical composition for inhibiting viral infection in a mammal, comprising: 1) an effective amount of an anti-TSG101 antibody; and 2) a pharmaceutically acceptable carrier, wherein said anti-TSG101 antibody binds to an epitope within the TSG101 C-terminal region consisting of the amino acid sequence recited in SEQ ID NO:3. ### Claim 18 A pharmaceutical composition for inhibiting viral infection in a mammal, comprising: 1) an effective amount of an anti-TSG101 antibody; and 2) a pharmaceutically acceptable carrier, wherein said anti-TSG101 antibody is selected from the group consisting of antibodies C, D1, E, 3G1 and CB8.